Carbon^2: Brine utilisation for CO2 capture and repurposing
Carbon^2, led by researchers from Sapienza University of Rome (Italy), Queen Mary University London (UK) and Bulgarian Academy of Sciences (Bulgaria), is one of the supported research teams in the first S3E Start Programme.
The Carbon^2 group provides expertise in converting industrial emissions and wastes to value added essential minerals. Using a specialised carbon capture and utilisation (CCU) technology, they generate application specific mineralized-carbon for downstream use in the infrastructure, agriculture and pulp & paper industries.
Carbonated material can be used in novel construction materials, revenues of which are expected to reach $1 trillion USD per year by 2030 (Utilization Panel Report: CO2 Conversion to Solid Carbonates). Magnesium sources are widespread worldwide (silicate deposits, wastewater, brine) and plentiful enough to sequester all anthropogenic emissions during the next 1000 years.
CO2 mineralisation has also the potential to manufacture CO2-negative construction materials which, in certain applications, could mitigate or even replace conventional Portland cement in a wide-scope of applications. Their CCU solutions provide particular advantage to the cement industry, itself responsible for 8% of man-made CO2 equivalent emissions and holds the highest carbon intensity of any industry per unit of revenue. Carbon^2 modular mobile units allow this group of experts to provide custom designed and hazard-free water-based solutions for location and waste specific processing. ensuring a clean transition to sustainably square away carbon.
Learn more about Carbon^2 by watching the pitch done by researcher Dr Gregory Chass during the Start Open Day on 20th July 2023.
https://youtu.be/WSikRty3cMc
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
Cancer Therapeutics: Targeting and destroying ovarian cancer cells
Cancer Therapeutics, led by researchers from Ca' Foscari University in Venezia and CRO Aviano (Italy), is one of the supported research teams in the first S3E Start Programme.
The team behind Cancer Therapeutics is introducing a revolutionary technology that presents a ground-breaking system designed for the treatment of solid tumour ovarian cancer, known as Copper Nitroprusside (CuNP).
Ovarian cancer ranks as the 7th most aggressive cancer in women globally, with a survival rate of less than 30%. In the year 2023, there were 314,959 newly diagnosed cases of ovarian cancer, resulting in 207,253 reported deaths. Among the various types of ovarian cancer, High Grade Serous Ovarian Cancer (HGSOC) is particularly aggressive, accounting for approximately 70% of ovarian carcinoma cases and exhibiting high mortality rates.
Traditionally, chemotherapy has been employed as the primary treatment for ovarian cancer. However, nearly 50% of patients develop resistance to the existing therapies, necessitating costly second-line treatments. This technology, named Copper Nitroprusside (CuNP), overcomes the limitations of current therapeutic approaches. It addresses issues such as cost reduction, biocompatibility, and the destruction of dense tumour matrices, which pose significant challenges in the field of cancer medicine. Moreover, this technology overcomes chemotherapy-related problems by simultaneously supplying multiple Reactive Oxygen Species (ROS) without the need for external stimuli. This unique system initiates the Fenton reaction with exceptional efficiency. Notably, these CDT agents possess the ability to generate multiple ROS and nitrogen-based reactive species at the tumour site, further enhancing their therapeutic effectiveness.
This remarkable enhancement obviates the need for additional drugs, external stimuli, or delivery systems. Significantly, no comparable system capable of generating dual ROS in cancer therapy with such high therapeutic efficacy and minimal side effects has been developed until now. Cancer Therapeutics’ product offers an effective approach to combat and overcome ovarian cancer, providing hope for patients in need of a more advanced treatment option.
Learn more about Cancer Therapeutics by watching the pitch done by researcher Kanwal Asif during the Start Open Day on 20th July 2023.
https://youtu.be/oijNBV4Ip9A
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
BioMEMs: Metallic implants that heal shockingly fast
BioMEMs, led by researchers from University of Aveiro (Portugal), is one of the supported research teams in the first S3E Start Programme.
An ageing population increases the incidence of orthopaedic injuries, affecting quality of life. Small bone lesions can often self-heal, but critical-sized defects require orthopaedic implants. Metallic materials like stainless steel and titanium alloys are the most used. These materials present great mechanical properties, load-bearing capabilities, and fatigue resistance, but lack in biological compatibility and suffer from corrosion and diminished cell adhesion.
When compared to titanium, 316L SS implants show inferior biological properties, but still present a big share of the market thanks to its lower cost. BioMEMs aims to solve the problem related to 316L SS, by depositing a bioactive PLLA based coating to establish a strong connection between bone tissue and the metallic implants. Their approach is inspired by the piezoelectric nature of bone and their research into PLLA bioactivity.
PLLA has been gaining attention due to its attractive properties such as biocompatibility, biodegradability, and piezoelectricity. Piezoelectricity plays an important role in the processes of regeneration and vascularization of the bone. BioMEMs have a bioactivated prosthesis that were characterised in vitro, assessing their cytocompatibility and osteogenic properties, and in vivo, by subcutaneous implantation in a rat animal model. Thus, their team expects that our technology can contribute to the development of the next generation bone implants that can simultaneously boost recovery speed and reduce rejection rate.
Learn more about BioMEMs by watching the pitch done by researcher Maxim Ivanov during the Start Open Day on 20th July 2023.
https://youtu.be/JnukeFh9dKg
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
Water2kW: the Spanish startup producing green hydrogen with eco-friendly technology
Water2kW is one of the supported startups in the first S3E Charge Accelerator Programme.
The technology developed by Water2kW enables the production and use of green hydrogen wherever it is installed. It requires only one source of energy, preferably from renewable sources, enabling the process to be 100% sustainable, using environmental humidity as sustainable water supply.
Their Humidity® technology provides another differential fact: the total use of the process by-products. Advanced by-product recovery systems are capable of 1) Recycling O2 to produce hydrogen peroxide or electricity 2) Recovering waste heat or 3) Taking advantage of the excess produced water. All this, without the need to add chemicals to the process and without generating emissions, rejections or toxic discharges, as is the case of current reverse osmosis and grey hydrogen installations. This new modular, circular and no-waste approach can significatively contribute to climate change objectives.
Learn more about Water2kW by watching the pitch done by their R&D Manager, Luisa Fraga, during the Charge Open Day on 6th July 2023.
https://youtu.be/E5RuQf2V3eE
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
ThetaBiomarkers: the Greek startup helping people decrypt their metabolism
ThetaBiomarkers is one of the supported startups in the first S3E Charge Accelerator Programme.
ThetaBiomarkers have created an innovative and technologically advanced clinical laboratory for the provision of quality metabolomics-based services for health and wellness, ensuring that final users get accurate treatment decisions. They are a deep-tech company that offers simultaneous analysis for a plethora of biomarkers and drugs, using state-of-the-art instrumentation, bespoke algorithms and sophisticated software. They offer evidence-based solutions, tailored to the needs of our customers, in order to provide a personalized metabolism tracker and personalized reports and wellness/health advice.
Also, they have developed convenient, safe and alternative to in-clinic visits testing options for different body fluids. They launched a new, innovative technology product for quick and easy sampling outside the clinical laboratory, avoiding costly cold chain transfers. The ability to sample and ship small volumes of liquid biosamples on a simple card enables uninterrupted monitoring of vulnerable or remote-located patients, especially in the post COVID-19 pandemic era.
They are at the spearhead of technology development generating new bioanalytical approaches, promoting application to numerous sectors and activities. Their scalable and customisable portfolio delivers unique added-value to researchers and healthcare providers to in-market wellbeing management.
Learn more about ThetaBiomarkers by watching the pitch done by their CEO, Olga Begou, during the Charge Open Day on 6th July 2023.
https://youtu.be/U0NGb-q-o5M
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
RespiBit: the startup providing personalised, predictive and protective solutions for healthy living with respiratory diseases
RespiBit is one of the supported startups in the first S3E Charge Accelerator Programme.
Problem: Asthma management is currently insufficient and needs to be improved as many of the current hospitalizations and deaths due to asthma are avoidable. Notably, asthma is the leading cause of hospitalization for children under the age of 18 today. Despite the significant costs and seriousness of the asthma problem, no solutions exist to effectively manage the condition or to predict asthma attacks.
Solution: The AsthmaFit system is the first predictive and personalized product to monitor and manage asthma in a deep and effective manner. It's a completely unique approach to monitor the condition of asthma patients, their exposure and symptom histories, and predicting asthma attacks by providing actionable, preventative and protective metrics.
Product/Services: The AsthmaFit product consists of a wearable device, an app and cloud software. AsthmaFit services address the specific needs of people with asthma of different severity (i.e., mild, moderate, and severe) and provide personalised solutions for monitoring asthma and minimising asthma attacks. AsthmaFit provides a unique and powerful solution by means of broad monitoring of exposure to the 3P’s (pollen, particulates and pollutants) that influence asthma in different ways, by monitoring individual symptoms, and by advanced algorithms that analyse the exposure entities, determine the sensitivity profile and then predict next day probable outcomes.
Value Proposition: AsthmaFit delivers to the user: a comprehensive exposure history in terms of pollen, particulates and pollutants, asthma status and sensitivity profile, and exposure warnings based on long-term exposure to specific irritants and short-term exposure to specific triggers. It is estimated that AsthmaFit will be able to predict 60%, or more, of severe asthma attacks reducing overall costs of asthma for people with severe asthma.
Learn more about RespiBit by watching the pitch done by their Founder and CTO, Aleck Alexopoulos, during the Charge Open Day on 6th July 2023.
https://youtu.be/OmnPhhTwM7E
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
Psychomeasure: the medtech startup decoding mental health
Psychomeasure is one of the supported startups in the first S3E Charge Accelerator Programme.
What? Psychomeasure© is a clinical tool based on natural language processing (NLP) to support physicians in their diagnosis and monitoring of schizophrenia patients, adding quantitative resources to the qualitative analysis of patients. Psychomeasure© is based on scientific research that has been produced from over one decade of ongoing interdisciplinary investigation and has already been submitted to clinical trials monitored by mental health experts.
Why? The traditional psychiatric diagnosis process is lengthy, subjective, and prone to errors. By using NLP technology, Psychomeasure© can significantly decrease the time of evaluation and diagnosis, adding precision and accuracy. Traditional diagnostic methods for schizophrenia rely on psychiatric evaluation, behavioural examination and medical history assessment. According to scientific literature, misdiagnosis of schizophrenia ranged between 39.16% and 56.7%. In contrast, their NLP solution has been found to have an accuracy of 90%.
How? Psychomeasure© provides a Software as a Service (SAAS) subscription-based product that provides cognitive markers based on speech that can be used in a similar way as a hemogram. These results are then used by psychiatrists to support their qualitative assessment of patients, enabling faster and more accurate diagnosis and patient monitoring.
The science behind Psychomeasure's algorithm was tested, validated, published, and awarded by some of the world's most renowned research centres, such as the Columbia University Medical School, the University of Edinburgh and King’s College in London. They currently have clinical trials taking place at hospitals and research centres in Europe and in Brazil using their Beta app. The company owns its intellectual property (IP) and has a formal agreement with the universities where it was initially developed.
Learn more about Psychomeasure by watching the pitch done by their CEO, Eduardo Barros, during the Charge Open Day on 6th July 2023.
https://youtu.be/t8L8pDqGa98
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
Inteligg: the Greek startup that will rocket your energy savings
Inteligg is one of the supported startups in the first S3E Charge Accelerator Programme.
c-BEMS is a unique cloud-based self-learning/adjusting Software-as-a-Service (SaaS) tool for Building Energy Management System (BEMS) that supports multi-zonal control of heating/cooling and lighting systems for energy savings of 40% in public and private buildings.
The Inteligg system also saves on the significant expenses based on the installation of the different devices necessary to create the local network, since only the internet is necessary to create the wireless network thus reducing also in this way 25% the expenses.
At the same time, Inteligg employs a certified and integrated IoT platform as the one of Niagara 4.1, provided by Tridium (USA) that secures the operation and homogeneous adaption of different devices (i.e. temperature sensors) and protocols in one unified platform, while being able to implement their own algorithms/software on the top of this platform; this way, they can provide these high energy savings on HVAC/lighting while checking remotely on real-time the operation of multiple buildings all over the world. Also, a real-time CO2 emissions calculator is provided to the building owners/managers/companies that can help them towards their ESG/UN objectives and their path to fighting climate change.
This patented technology is unique and the use of AI brings a major advantage and a unique selling point globally compared to any other existing solutions.
Learn more about Inteligg by watching the pitch done by their CEO and Co-founder, , during the Charge Open Day on 6th July 2023.
https://youtu.be/5aRBAFGm9zI
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our newsletter
Follow us on Twitter and LinkedIn
IIO: the ideal VaaS solution for new applications and voice services deployment
IIO is one of the supported startups in the first S3E Charge Accelerator Programme.
IIO is a Voice-as-a-Service (VaaS) platform for Customer Experience Management, equipped with human voice and emotion recognition for B2B and B2B2C markets, ideal for different business needs of different departments, such as Marketing, Sales, HR and Customer Care.
IIO is based on the revolutionary combination of three key elements to offer an unprecedented Customer Experience, Engagement & Relationship Management experience:
- Adaptive Conversational Engine (ACE): At the heart of IIO is the proprietary ACE conversational platform, a patented technology that uses emotion recognition and generative AI to create natural and engaging speech interactions.
- Recognition of human emotions: The emotion recognition technology integrated in IIO allows the platform to perceive the customer's mood and adapt to her mood.
- Generative AI: IIO leverages advanced generative AI engines, such as OpenAI, Bard, and Jasper, to quickly learn and generate relevant responses in any language.
IIO emerges as an innovative solution in the customer relationship management landscape, distinguishing itself from traditional solutions and allowing companies to reduce operating costs, increase sales opportunities and optimize customer engagement strategies.
Learn more about IIO by watching the pitch done by their Founder and CEO, Pasquale Bombino, during the Charge Open Day on 6th July 2023.
https://youtu.be/IX6ogAmg-lQ
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu
Looking forward to exploring synergies and creating a long-lasting collaboration.
Explore our website and subscribe to our Newsletter
Follow us on Twitter and LinkedIn
Grawindy: the Turkish wind-agrotech startup shaping the future of energy industry
Grawindy is one of the supported startups in the first S3E Charge Accelerator Programme.
Grawindy is a core wind technology designed on the principle of regulating the unpredictable and variable power values of moving parts (sails). What is particularly unique about Grawindy, is its ability to operate in low wind speeds (3 m/s) in any wind speed/direction. This is an important distinction from wind turbine technology as it means the unit does not need to be oriented towards ‘prevailing winds’ or ‘seek wind’ to function at optimum capacity. Further, flexibility of location is heightened by its ability to be assembled and disassembled easily.
Learn more about Grawindy by watching the pitch done by their CEO, Atilla Öztürk, during the Charge Open Day on 6th July 2023.
https://youtu.be/UgWRB3sICl4
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu